Dr. MUNEER ALBAGSHI Consultant Pediatric Hematologist Oncologist- HBDC, Al-Ahsa. Saudi Arabia

Similar documents
How to Write a Life Care Plan for a Child with Hemoglobinopathy

Medical and Surgical Complications of Sickle Cell Anemia

Health Maintenance and Education for Children and Adults

Bridging the Gap: Improving Sickle Cell Disease Transition from Pediatric- to Adult-Focused Care ASFA 2017 Annual Meeting

Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease

Anemia s. Troy Lund MSMS PhD MD

SICKLE CELL DISEASE. Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH. Assistant Professor FACULTY OF MEDICINE -JAZAN

Sickle Cell Disease Integrated Care Models: Outpatient and Inpatient National Minority Quality Forum April 2017

Sickle cell disease. Fareed Omar 10 March 2018

SICKLE CELL DISEASE TO TREAT OR

Comprehensive Care for Children and Adolescents with Sickle Cell Diseases

Sickle Cell Disease. Edward Malters, MD

Rationale for RBC Transfusion in SCD

Hematology/Oncology/BMT

Dr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW

1. Adequate diet and iron intake to prevent iron deficiency 2. Signs and symptoms of malignant disease

Aneurin Bevan University Health Board Sickle Cell Anaemia and Haemoglobinopathy Screening and Management in Pregnancy Guidelines

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

CURRENT RESEARCH STUDIES

Congenital Haemoglobinopathies

Multidisciplinary care. Michael Angastiniotis

SCD Advocacy Talking Points!

How to Increase Awareness Lanre Tunji-Ajayi. President/Executive Director; SCDAC/AAFC

Putting some hematology into Pediatric Hematology/Oncology: a review of Hemophilia and Sickle Cell Disease in the Pediatric Patient

HbSC disease is it different and how should we manage it? David Rees Department of Paediatric Haematology, King s College Hospital, London

Hemolytic anemias (2 of 2)

SICKLE CELL BROCHURE

Kenya Sickle Cell Care

Achieving a Better Understanding of the Impact of Sickle Cell in Indiana CHeP Pilot Project Symposium Gary Gibson Monica Khurana Marc Rosenman

Sickle Cell Anemia A Fictional Reconstruction Answer Key

Dependance on chronic transfusion

Transfusion in Sickle Cell Disease What the guidelines [are likely to] say. Dr Bernard Davis Whittington Hospital, London

Sickle Cell Disease and impact on the society

Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017

COHEM Barcellona 2012 Hemoglobinopathies debate

Thalassemia Maria Luz Uy del Rosario, M.D.

Integrating Medical and Social Support for Elderly System & Technology Enabled Service Innovations. Dr Christina MAW Hospital Authority, Hong Kong

Blood Transfusions in Children with Haemoglobinopathies

Community Genetics. Hanan Hamamy Department of Genetic Medicine & Development Geneva University Hospital

6 th EUROPEAN SYMPOSIUM ON RARE ANAEMIAS 1 st Dutch-Belgian meeting for patients and health professionals

Subspecialty Inpatient Rotation: Pediatric Oncology at Memorial Sloan Kettering Cancer Center Senior Resident

Hydroxyurea Treatment for Sickle Cell Disease

An overview of Thalassaemias and Complications

Inputs from Medical Unit, Ministry of Social Security and Ministry of Health Mauritius1

Introduction reduction in output alter the amino acid sequence combination

Newborn Screening and Followup for Hemoglobinopathies

Striving for better health

Palliative Care Quality Improvement Program (QIP) Measurement Specifications

Tusculum College. Benefit Summary. $25 Copay. $25 Copay. after Deductible. 20% after Deductible 20% after Deductible

SICKLE CELL DISEASE TREATMENT DEMONSTRATION PROGRAM. CONGRESSIONAL REPORT Executive Summary

Sickle Cell Anemia. Sickle cell anemia is an inherited disorder of the blood which occurs when just one base pair substitution

Compassionate-use Voxelotor (GBT440) for up to 2 Years in Patients With Severe Sickle Cell Disease and Life-Threatening Comorbidities

Sickle cell disease (SCD) and other hemoglobinopathies

Hydroxyurea (Hydroxycarbamide) - Guidelines for treating children with Sickle Cell Disease

Hemoglobinopathies NORMAL HEMOGLOBINS

Genetic Modifiers of Sickle Cell Disease Severity. Kunle Adekile, MD, PhD Professor Department of Pediatrics Kuwait University

Making Hope A Reality December 10, Nasdaq : BLUE

Sickle Cell Disease: Myths and Realities. Marsha Treadwell, PhD Wanda Payton Williams, MS 6 August 2014

Tusculum College. Benefit Summary Option/Quote: 2. 30% after Deductible. $35 Copay. 30% after Deductible

The use of red cell genotyping in the management of sickle cell disease

Hydroxycarbamide. Sickle and Thalassaemia Training days. September Dr Sara Stuart-Smith. Why do sickle cells cause pain and organ damage?

Welcome to Sickle Cell Disease by Connie Martin, MS, RDN; Lolita McLean, MPH, RDN; and Claire Stephens, MS, RDN of the Alabama Department of

Newborn Screening for Sickle Cell Disease in Africa: Public health meets reality

1 Kattamis et al. Growth of Children with Thalassemia: Effect of Different Transfusion Regimens. Archives of

Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC

Cancer Survivorship NEURO-ONCOLOGY PATIENT SURVIVORSHIP PLAN. Resources and Tools for the Multidisciplinary Team

Sickle Cell Disease: How Should YOU Reassess Management & Treatment?

Siklos. Siklos (hydroxyurea) Description

110 DISEASES 3 DISEASES GENE TIC COUNSELING CARRIERMAP Recombine. Others. 30+ minute clinical genetic counseling session.

Acute Complications of Sickle Cell Disease

Tenth Visit posttest

TRANSFUSION PRACTICES IN THE MANAGEMENT OF SICKLE CELL DISEASE AMONG FLORIDA PHYSICIANS

Sickle cell disease: Complications in adult patients

The Voice of Sickle Cell

Bedfordshire, Luton and Milton Keynes (BLMK) Sustainability and Transformation Partnership (STP) Central Brief: October 2017

The sickle cell outpatient service Information for adult patients with sickle cell disease

Obiageli E. Nnodu Associate Professor of Haemato-Oncology Centre for Sickle Cell Disease Research and Training (CESRTA) University of Abuja

Education Visit #1 *** All Sickle Cell Patients*** from A Parent s Handbook for Sickle Cell Disease Booklet.

Instructor s Manual Chapter 26 Hematological Alterations. 1. A man and woman both test positive for the sickle cell trait. The couple asks the

Hydroxyurea. for Sickle Cell Disease. A Guide for Starting Treatment. Hydroxyurea is a medicine proven to prevent pain from sickle cell disease.

Cedars Sinai Medical Center Pediatric Electives

SCHEDULE OF BENEFITS PLAN M7

Newborn Screening for Sickle Cell Disease in Ghana Update

REACHING OUT IMPROVING TRIBAL HEALTH

Siklos (hydroxyurea) NEW PRODUCT SLIDESHOW

Sickle Cell Disease an Overview

Neonatal Screening for Genetic Blood Diseases. Shaikha Al-Arayyed, PhD* A Aziz Hamza, MD** Bema Sultan*** D. K. Shome, MRCPath**** J. P.

The County of Santa Clara

The NHLBI s Health Disparities Efforts. Helena O. Mishoe, Ph.D., M.P.H. NHLBI April 19, 2010

Your sickle cell disease story

Managing Emergencies

Bridge Team Innovation: New Approach to Care Management for Sickle Cell Disease:

*GERIATRIC FELLOWSHIP COMPETENCY CHECKLIST EDUCATIONAL GOALS:

Thalassaemia. What is thalassaemia? What causes thalassaemia? What are the different types of thalassaemia?

Toronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action

Assessment of SRH Integration in Selected Arab Countries Jordan Country Report. Expert Group Meeting Tunis Presented by: Maha Saheb, MD

performance measurements. Nurses were trained as case managers and clinical auditors of diabetes care.

World Cancer Congress, August 2012, Montreal, Canada

Strategy for Suicide Prevention July 2013

Transcription:

Dr. MUNEER ALBAGSHI Consultant Pediatric Hematologist Oncologist- HBDC, Al-Ahsa. Saudi Arabia

Sickle cell is global disease of old world and immigrants to the new world. Sickle cell anemia to predict that the number of cases in newborns is likely to rise to about 404 200 in 2050, up from 305 800 in 2010 (1) It has linear relation with previously endemic with Malaria as protective mutation to preserve the native population. 1.T Biswas. Global burden of sickle cell anaemia is set to rise by a third by 2050 BMJ 2013;347:f4676

Sickle cell gene distribution and Malaria Encyclopedia Britannica, Inc.

S haplotype background ( Bitoungui et al, 2015)

Sickle cell disease management is a comprehensive, multidisciplinary approach which includes a collaborative effort between patients, family members and the healthcare team. The management is not only physical, Psychologic aspect is high. It need dedicated team for proper management. Despites efforts in research and funds, many patients do not receive proper medical care.

The American family medicine association: Primary care physicians should be familiar with SCD: Pathophysiology Diagnosis, evaluation. Current standard of care (basic care, vaccinations, periodic investigations). Medical management of sickle cell disease. When to refer. (1) 1.J Family Med Prim Care. 2012 Jan-Jun; 1(1): 56 58. doi: 10.4103/2249-4863.94454 2. ASH Education Book December 6, 2013 vol. 2013 no. 1 433-438

Unfortunately primary care physicians and workers has less knowledge about the health care delivery for SCD patients. Efforts made to transform primary care into a centerpiece for improving health care quality in USA. The patient-centered medical home (PCMH) is the example of chronic care for chronic disease to improve the outcome. (1) 1.Bitton A(2011) Who is on the home team? Redefining the relationship between primary and specialty care in the patient-centered medical home. Med Care 49(1):1 3

Many morbidities could be solved early, but they are not. More burden to health system (finance, manpower, time ) USA: each admission lasted 5.1 days and cost per (patient or per admission) patient was $7,637.95. In five years, 37 patients spent 863 days in the hospital with a total cost of $1,283,176.83. (1) Psychosocial on the patient, his family, and the community with rise unemployment, etc.. 1.Blood 2014 124:5971;

Retinopathy Auditory impairment Hepatomegaly Gall stones Cholestasis Renal: enuresis, papillary necrosis, hyposthenuria. Mesenteric occlusion Priapism Growth Retardation Chronic Anemia Stroke Psychological implications Heart failure Pulmonary HT Acute Chest S. Splenomegaly Delayed puberty Reduced fertility Obstetric complications Skeletal: Acute pain Chronic pain Osteonecrosis, Infection BM expansion Hand-Foot S.

Distribution of SCD in the kingdom: certain regions No national or local registries No early diagnosis(neonatal screening) Limited access to medical care in many villages, and towns. Many patients undiagnosed. Guidelines developed and not popular or not known by the practitioners. Limited training for PHC doctors especially in highly prevalent areas. Medications and laboratory services limitations. 30-40% of adult medical bed occupancy by SCD patients. The system of care is not integrated one and drain resources.

Healthcare models used in cystic fibrosis and hemophilia (conditions that require lifelong multidisciplinary care) may provide helpful frameworks for SCD. It knowledgeable practitioners and a coordinated system of care throughout the patient s lifespan. SCD patient live longer than the past, thereby need more care. Expand the services for unreached patients.

There are several SCD model of care worldwide. Primitive services center of excellence Scattered services integrated system Simple complicated

Ministry of health studied health care system and in the VRO formed chronic diseases care unit. Model of care (MoC) unit studied the redesign the health delivery system. The aim is to have an integrated health care models. The regions were assigned different diseases SCD chosen in Eastern province (KFSH-D) is the base.

To adopt Integrated system High yield benefits Simple in application Measurable process and outcome Track patients Reflect the patients need Long term economic

SCD MOC Sickle cell disease has a much higher prevalence in the Eastern Province than other areas. Eastern Province population have the sickle cell trait 24% and 1.2% have sickle cell disease. Therefore improving the sickle cell pathway is of strategic priority within the Eastern Province.

Chronic Care OVERVIEW: MODEL OF CARE FOR SAUDI Physical wellbeing Social wellbeing Mental wellbeing Planned Care Workforce ehealth Private-Sector Participation Payment Mechanisms Governance & Regulation

Chronic Condition The system will support patients and their bereaved families during the last phase of their lives by providing them with compassionate care and empowering them to spend their last days where they are most comfortable The system will support people to stay well and get well again by empowering them with knowledge and supporting them with healthy communities The system will support people to manage their chronic conditions by providing Integrated care and ease patient flow between care settings, and promoting care at the appropriate setting Physical wellbein g Social wellbein g Mental wellbein g Planned Care The system will support patients receive a great and consistent - outcome for their planned procedures, by providing necessary, efficient, and quality care The system will support people when they have an urgent problem by providing needed treatment in the right place at the right time and supporting patients to return home and to community services The system will support women have a safe delivery and healthy infants by providing continuous support from pre-marriage and pre-conception to post-delivery and during early years development From PATHWAY MANUAL CHRONIC CONDITIONS Model of Care.MOH. August 2017

Preventive initiatives Early detection Defined role for primary health care centers Hereditary blood disease centers Secondary care hospitals role Emergency department Admissions (inpatient services)

Three levels of prevention 1- Public awareness: the disease and the importance of follow up in the disease category 2- Pre-marital screening initiatives and genetic counselling to inform prospective parents about the risks of their children inheriting the disease. 3- Preimplantation genetic diagnosis (PGD) (i.e. screening for embryos that do not carry the sickle cell trait before implantation).

Screening levels Neonatal screening esp. in high risk regions Family members of high risk group ( parents S trait, affected parent) Population at risk and those not screened in the neonatal period Primary healthcare centers (PHC) and inherited blood disease centers, and hospitals. Aims Build national registries Enroll the patients in comprehensive care program. Social security support

PHCs roles: Diagnosis Health Education Genetic Counselling. Infection prevention: vaccinations: HIB,MCV4, PCV13, PPSV23, Influenza. Surveillance for chronic complications shared with IBDC through case coordinators. Refill medication (HU) and share follow up. Family doctors will be trained in SCD management complications and chronic pain. PHCs will be enhanced through the Enhanced Primary Care intervention as part of the national Model of Care. Patient segmentation level1 and 2

Patient Segmentation Patients segmentation More common in HbSS and HbSß -0 thalas. genotypes More common in HbSC and HbSß + -thalas. genotypes. Level 3: severe symptoms and major complications Require education, admissions in dedicated clinics and tertiary care procedures Level 2: medium symptoms and few minor complications Mainly require education, regular check-ups in PHCs and ad-hoc home care assistance Level 1: mild symptoms 1 Mainly require education and regular checkups in PHCs 1+ ACS Cerebral infarcts Hepatic sequestration Splenic sequestration Frequent painful crises leading to hospitalization Medium painful crisis Bone necrosis Priapism Leg ulcer Congestive heart failure Mild painful crisis Thrombotic crises Minor failure to thrive Adults (15+ years) Pediatric (up to 14 years) Age group Patients by segment 28.0 Eastern Cluster 20.7 4.1 (20%) 10.3 (50%) 6.2 (30%) Adults Pediatric 7.3 4.4 (60%) Level 3 Level 2 Level 1 0.7 (10%) 2.2 (30%) 1. This segment includes also patients with very mild/ no symptoms at all. Source: Evidence-based management of Sickle Cell Disease, NHLBI (2014); Development and validation of a pediatric severity index for sickle cell patients, American Journal of Hematology (2010); Evaluation of clinical severity in sickle cell disease, Journal of the National Medical Association (1983)

Roles Confirm sickle cell diagnosis Keep up registry Receive education for adult and pediatric families. These centers could be co-located with secondary care hospitals to enable better integration. Plan of care follow-ups will be carried out in PHCs with their family physician. Patient assignment according to the segmentation (along with hospital SCD doctors) Special procedures: TCD, US, X-rays, dexa scan, echocardiogram, ECG Prescribe hydroxyurea and its plan and any other drugs IBDC will keep annual visits for the patients for low risk, and special care consultations. The clinic will allow easier case coordination of sickle cell patients with case coordinators working at the clinic full time, coordinating patients through all service layers and settings. Patients should also be able to attend these clinics for pain episodes to alleviate the burden on EDs and receive pain management from staff trained to manage the disease, ( a Later stage).

The team will adopt or create comprehensive care program for SCD. Virtual Self Care Tools may also be used to enable the patient and family to manage their condition at home, as well as education about potential complications and time table for appointments and consultations.

Chronic complications to IBDC or directly to hospital through case coordinators (AVN, gallstones, hypersplenism, iron overload) Acute complications to emergency department.

The need for admissions are still to treat certain complications Acute complications: Acute severe pain episode ACS Stroke etc.. Chronic complications: Hips surgeries Gallbladder stones Splenectomy

The role is limited to few referrals Stem cell transplantation. Other transplantations: liver, heart. Hip replacement: (secondary)

Human Resources : case coordinators, family doctors, health educators, nurse practitioners, lab tech. IT tech. Ancillary Resources: networking, electronic files and single integrated health information system that every one share the information, health education tools, Laboratory: Hb electrophoresis, kits, availability of tests and good utilization of resources. TCD, Ferritin, vit D Pharmacy: empower with medications HU, NSAID, Opioid. Development of SCD management guidelines. Training, training

Segmentation and sampling SCD Patients Patients segmentation More common in HbSS and HbSß -0 thalas. genotypes More common in HbSC and HbSß + -thalas. genotypes. Level 3: severe symptoms and major complications Require education, admissions in dedicated clinics and tertiary care procedures Level 2: medium symptoms and few minor complications Mainly require education, regular check-ups in PHCs and home care assistance Level 1: asymptomatic Mainly require education and regular checkups in PHCs 3 painful crisis per year 1+ ACS Pulmonary hypertension Chronic lung disease Cerebral infarcts Priapism Leg ulcer Hepatic/ Intrahepatic sequestr. Splenic sequestr./ Splenectomy Cholestasis Congestive heart failure Thrombottic crises Bone necrosis (late stage) Alloimmunization 1/2 painful crisis per year Bone necrosis (early stage) Stable proteinuria Asymptomatic gallstone Growth failure Hypertension Diabetes No symptoms No complications Age group Adults (15+ years) Pediatric (up to 14 years) Example Sample size Level 3 Level 2 Level 1 # of enrolled patients Adults Pediatric Adults Pediatric Adults Pediatric 224 119 336 166 470 213 Total 1,528 Defined sample size ensure enough patients per segment to test the pathway while maintaining model representativeness Source: Evidence-based management of Sickle Cell Disease, NHLBI (2014); Development and validation of a pediatric severity index for sickle cell patients, American Journal of Hematology (2010); Evaluation of clinical severity in sickle cell disease, Journal of the National Medical Association (1983); A.T. Kearney

1- it addresses issues from current status 2- it combine new interventions as well as cross-cutting interventions that is applicable to all systems of care. 3- it is patient centered as well as integrated 4- it is monitored by KPIs It is sustainable financially. Examples : A- Emphasis on public awareness and health education for both families and patients who utilize virtual educational tools and virtual self care tools. B- Focus on prevention: hydroxyurea available in PHCs to reduce pain and ED visit and addiction C- PGD for high risk couples to produce well babies D- Higher levels of efficacy and productivity Reduce ED visits so it will be utilized by different patients Through IBDC different providers are able to access patients files, prescriptions for continuity of care.